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ABSTRACT 
Obesity has been associated with poor health outcomes in breast cancer survivors. Thus, 
weight loss is recommended for overweight and obese survivors. We systematically reviewed 
studies (published up to July 2013) that evaluated behaviorally-based, weight loss 
interventions in women with breast cancer exclusively. Completed randomized trials, single-
arm trials and ongoing trials were reviewed. Within-group and between-group differences for 
weight loss were extracted, as was data on secondary outcomes, i.e., clinical biomarkers, 
patient-reported outcomes, adverse events. Ten completed randomized trials, four single-arm 
trials and five ongoing trials were identified. Statistically significant within-group weight loss 
was observed over periods of 2-to-18 months in 13 of the 14 trials, with six randomized and 
two single-arm trials observing mean weight loss ≥5%. Clinical biomarkers, psychosocial and 
patient-reported outcomes were measured in a small number of studies. No serious adverse 
events were reported. Only two trials assessed maintenance of intervention effects after the 
end-of-intervention and none reported on cost-effectiveness. The studies included in this 
review suggest that weight loss is feasible to achieve and safe in women following treatment 
for breast cancer. Future studies should assess (and be powered for) a range of biomarker and 
patient-reported outcomes, and be designed to inform translation into practice. 
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INTRODUCTION 
Over 50% of breast cancer survivors in Western countries are overweight or obese (1-4). 
Furthermore, most women undergoing breast cancer treatment will gain weight either during 
or following treatment (5). Excess body weight at diagnosis is associated with poorer breast 
cancer outcomes, with meta-analyses of observational studies reporting 20-43% higher risk of 
breast cancer-specific and overall mortality in obese women compared to healthy weight 
women; data are similar for pre- and post-menopausal women (6; 7). Obese women also have 
a 46% higher risk of distant metastases (8) and more than double the risk of any recurrence 
(9). The effect of post-diagnosis weight gain has been mixed (5; 10; 11). 
 
The association between obesity and survival is variable across sub-groups, with no 
significant associations observed in women with triple negative breast cancer for either 
recurrence or overall survival (12; 13). Studies in specific ethnic groups, such as African-
Americans and Hispanics, have shown weaker associations than those observed among 
Caucasians (14-16). 
 
However, it is still unknown whether intentional weight loss improves outcomes for women 
with breast cancer. The Women’s Intervention Nutrition Study (WINS; n=2,437) evaluated, 
in a randomized controlled trial (RCT), the impact on disease-free survival of a low-fat 
dietary intervention (individual face-to-face counseling sessions, of decreasing frequency 
over five years) compared to control (17). Although  weight loss was not targeted, women in  
the intervention lost ~4% of initial body weight, and experienced lower rates of  recurrence 
(HR = 0.76; 95% CI 0.60, 0.98), with a suggestion that this effect was stronger in women 
with estrogen receptor-negative (HR = 0.58; 95% CI 0.37, 0.91) and progesterone receptor-
negative (HR = 0.54; 95% CI 0.35, 0.83) disease (17). In contrast, the Women’s Healthy 
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Eating and Living (WHEL) study (n=3,088), did not observe  differences in recurrence (HR = 
0.96; 95% CI 0.80, 1.14) or survival (HR = 0.91, 95% CI 0.72, 1.15) with a low-fat, high fruit 
and vegetable diet (individual telephone counseling sessions, of decreasing frequency over 
four years), however participants were on average weight stable (18). Although other 
differences exist between the trials (19), weight loss in the WINS trial is a possible 
mechanism behind the lower recurrence.   
 
Leading cancer organizations recommend that cancer survivors achieve and maintain a 
healthy body weight and promote modest weight loss (5-10%  body weight) for those who 
are overweight/obese (20; 21). These recommendations are primarily driven by cancer 
survivors’ substantial comorbidity (e.g., cardiovascular disease and diabetes), and the 
favorable influence of weight loss on these (22).  Nevertheless, very few women are advised 
to manage their weight and improve their lifestyles by their oncologists (23; 24). Evidence on 
the benefits and (lack of) harms of intentional weight loss for women following treatment for 
breast cancer (10) is needed to support implementation of such programs as part of routine 
follow-up care. 
 
The number of trials of weight loss interventions in breast cancer, while increasing, is still 
small, especially when compared to those on exercise and breast cancer, which have 
demonstrated benefits both during and after treatment on fatigue, depression, quality of life 
(QOL) and physical functioning (25; 26).   Further, there is currently no systematic review on 
the benefits of weight loss across various breast cancer outcomes. Our aim was to 
systematically review the evidence from weight loss intervention trials in women with breast 
cancer. The review sought to identify the magnitude of weight loss achieved and the effect on 
breast cancer-related and general health outcomes, including anthropometric measures, 
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treatment-related side-effects, psychosocial indices, clinical biomarkers, changes to dietary 
intake and physical activity (PA), and adverse events.  
 
METHODS 
Search strategy and eligibility criteria 
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (27), articles were identified through a structured search of PubMed, 
EMBASE and Web of Science up to July 1, 2013 with no date restrictions, limited to 
English-language.  The following search terms were used to search titles and abstracts: 
[‘intervention’ OR ‘program*’ OR ‘trial’] AND [‘RCT’ OR ‘random*’ OR ‘control*’ OR 
‘condition’] AND [‘breast’ AND (‘cancer’ OR ‘neoplasm’ OR ‘carcinoma’ OR 
‘malignan*’)] AND [‘weight loss’ OR ‘weight-loss’ OR ‘weight management’ OR ‘weight 
control’ OR ‘weight maintenance’ OR ‘weight maintaining’ OR ‘weight change*’ OR 
‘weight reduc*’]. 
 
Key author searches and manual searches of reference lists of included studies and recent 
review articles were conducted. Titles and abstracts were screened by one author (MMR) to 
determine eligibility. If unclear, the full-text was independently reviewed by two authors 
(MMR/COT), with differences resolved by discussion. For inclusion, the study had to be 
conducted exclusively in women with breast cancer, and report on the outcomes of an 
intervention trial evaluating a weight loss (not weight gain prevention) intervention. The 
intervention had to be behaviorally-based, i.e., promotion of an energy-restricted diet with or 
without PA, not weight loss as a result of pharmacologic or surgical intervention. RCTs were 
of primary interest, and could have included an intervention and control group or two 
intervention groups. Single-arm (pre- post-test) intervention studies also were included. 
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Ongoing trials identified in the search (e.g., protocol publications) were also reviewed, as 
these included a number of large-scale trials with survival endpoints.    
 
Data extraction 
Data were extracted and tabulated by one author (COT) and independently reviewed by 
another (MMR), with differences resolved by discussion. Extracted data included: study 
design; country; sample size; eligibility criteria (age; menopausal status; BMI; stage; time 
since diagnosis/treatment); participant characteristics (mean age, BMI, time since diagnosis, 
ethnicity); retention rate; description of the study groups (intervention: duration, frequency 
and number of contacts, modality of delivery, behavioral targets; details of treatment 
provided to control/usual care groups); and outcomes measured. Within- and between-group 
changes in weight with significance were extracted (reported as kilograms or percent of 
initial body weight). If within-group significance was not reported this was calculated from 
mean and standard deviation of change, if available. If change in body weight was not 
expressed as percent of initial body weight, estimates from the absolute weight change in 
kilograms and baseline weight were calculated. Studies were classified by mean within-group 
weight loss of ≥5% of initial body weight (20). Within-group and between-group significance 
for changes in other outcomes of interest also were extracted. Within-group changes in 
clinical biomarkers were expressed as percent change from baseline ([change/baseline 
value]*100), and their associations with magnitude of weight loss were considered. The 
primary focus was on end-of-intervention outcomes. If information was missing or unclear, 
authors and clinical trials registers were consulted.  
 
Risk of bias of included studies was independently assessed by two authors (MMR/COT) 
using a 10-item checklist (28; 29) (Table S1), based on the Consolidated Standards of 
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Reporting Trials (CONSORT) statement (30), and the Cochrane Handbook for systematic 
reviews of interventions (31). Each item was scored ‘present’ [1-point], ‘absent’ [zero-points] 
or ‘unclear or inadequately described’ [zero-points], with disagreements resolved by 
discussion. Each study was assigned a risk of bias category: high risk [0-3], moderate risk [4-
7] and low risk [8-10]. Risk of bias was assessed for single-arm trials against six criteria 
(Table S2), and was categorized based on: high risk [0-2], moderate risk [3-4] and low risk 
[5-6]. Due to the small number of studies, trials were not excluded based on the risk of bias 
assessment. 
 
RESULTS  
A total of 577 articles were identified (Figure 1). After removing duplicates (n=202), and 
excluding articles based on title and abstract (n=336), 39 publications were closely examined. 
Ten were subsequently excluded, leaving 29 publications included in the review – 10 
completed RCTs (15 publications), four single-arm intervention trials and five ongoing trials 
(10 publications).   
 
Completed randomized clinical trials 
Details of the 10 RCTs included in the review are shown in Table 1. The methodological 
quality of these was quite poor. Risk of bias was considered high in five (32-36), moderate in 
four (37-40), and low in only one (41) (Table S1). 
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Figure 1. PRISMA flow chart of studies through the review process 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample sizes ranged from 24 (35; 37) to 102 (32), with half recruiting <50 participants (33; 
35-38). Six-of-10 trials recruited both pre- and post-menopausal women (33; 34; 37-39; 41), 
two recruited only post-menopausal women (32; 36) and two were unspecified (35; 40). Only 
four studies reported mean time post-diagnosis for participants,(34; 36-38) ranging from 3.5-
5.6 years. Only one trial limited recruitment to a particular subtype of breast cancer and here, 
the defined subtype was broadly classified as estrogen receptor-positive (36). Seven-of-ten 
trials reported on ethnicity; five of these recruited Caucasians predominantly (33; 34; 36; 39; 
41), and two exclusively recruited African-Americans or Hispanics (37; 38).  
 
Six-of-10 trials evaluated weight loss interventions addressing both diet and PA (33; 34; 37-
39; 41) with the other four addressing diet only (32; 35; 36; 40). While most interventions 
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were delivered face-to-face, three studies evaluated interventions delivered via telephone (33; 
37; 39). Seven-of-10 trials evaluated a weight loss intervention compared to a control group 
(32-35; 38; 40; 41), with two of these studies also comparing to at least one other intervention 
group (33; 40). Three studies compared two intervention groups only (36; 37; 39).   
Intervention duration was less than 6-months in two trials (34; 35), 6-months in four trials 
(36; 38; 40; 41) and 12-months or longer in the other four (32; 33; 37; 39). Only one trial 
evaluated outcomes after a period of no intervention contact (38).  
 
Single-arm trials 
Details of the four single-arm trials included in the review are also shown in Table 1. One 
trial was considered to have high risk of bias (42) with the remaining three having moderate 
risk (43-45) (Table S2). The four single-arm trials recruited between 10-34 participants. 
Three included both pre- and post-menopausal women (42; 44; 45) and one included post-
menopausal women only (43). Participants were recruited, on average, 2-3 years after 
treatment completion (43; 44). One study recruited African-American women exclusively 
(45), with the others recruiting predominantly Caucasians (43; 44) or not reporting on 
ethnicity (42). Three-of-four trials evaluated a 6-month, group-based intervention (43-45); in 
one, the group sessions were conducted via conference call (43). One study evaluated an 8-
week diet and exercise intervention with thrice weekly supervised exercise sessions (42). 
Only one study followed-up participants post-intervention to assess whether changes in 
outcomes were maintained (44). 
 
Weight and anthropometric outcomes 
Weight change outcomes are shown in Table 1. Significant within-group weight loss was 
observed in intervention groups in all RCTs and single-arm trials except for one, where 
11 
 
within-group significance could not be calculated (37). Mean weight loss of ≥5% initial body 
weight was observed in at least one of the intervention groups in six-of-10 RCTs (32-34; 36; 
39; 40) and two of the single-arm trials (43; 44). Of the seven RCTs that compared the weight 
loss intervention to a control group, all except one (41) observed a statistically significant 
effect for weight loss (32-35; 38; 40). Of the studies that compared different weight loss 
interventions (33; 36; 37; 39; 40), no significant differences in weight loss were observed, 
with the exception of the study by Harris et al (39).  
 
Five-of-10 RCTs and three-of-four single-arm trials also reported on changes in waist 
circumference (34; 36; 38; 39; 41-44); six RCTs and two single-arm trials reported changes 
in adiposity (33; 34; 36; 38; 40-42; 44); and three RCTs and one single-arm trial reported 
changes in lean body mass (LBM) measured via Dual-energy X-ray Absorptiometry (DXA) 
(34; 36; 38). Waist circumference was significantly reduced in all of the intervention groups 
and percent body fat significantly reduced in all except one (41). No significant changes in 
LBM were observed in two trials (34; 38), whereas significant reductions in LBM were 
observed in the other two trials (36; 44).   
 
Clinical biomarkers 
Six-of-10 RCTs and three-of-four single-arm trials measured clinical biomarkers (34; 36; 38; 
39; 41; 46). Glucose and/or lipids were measured in all except two trials (42; 43); changes in 
these were inconsistently associated with weight loss both across the range of biomarkers 
assessed within studies and across studies. The most consistent changes were reductions in 
LDL-cholesterol and glucose. Two RCTs measured blood pressure (36; 41) – in one trial 
systolic blood pressure reduced in the low fat diet intervention but not the reduced 
carbohydrate diet group, with no change in diastolic blood pressure in either (36); whereas in 
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the other trial diastolic but not systolic blood pressure was significantly lower in the 
intervention group compared with control (41).  
 
Five RCTs (36; 38; 41; 46; 47) and three single-arm trials also measured biomarkers that 
have been associated with breast cancer progression (i.e., insulin pathways, adipokines and 
inflammatory markers) (48). Changes in these are shown in Table 2. Six trials measured 
insulin and/or insulin resistance (36; 38; 41; 43; 44; 46). Trials reporting weight losses of 
≥5% observed reductions in insulin and insulin resistance of 15-40% (36; 43; 44; 46). 
Insulin-like growth factor-1 (IGF-1) and IGF binding proteins were measured in two trials 
(38; 41), which reported weight losses of <5% and no within- or between-group differences 
were observed (38; 41). Changes in leptin were assessed in three trials (41; 43; 46); with 
leptin concentrations on average reduced by 12-40% in intervention groups. Total 
adiponectin was measured in two trials (38; 43). There was no significant within- or between-
group difference in adiponectin, and adiponectin concentrations did not change in the 
expected direction with magnitude of weight loss in these trials. 
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Table 1. Trials of weight loss interventions in women with breast cancer* 
Study/ 
Bias Score¦ 
Sample Study Arms/Intervention Characteristics Outcomes/Comments 
Randomized controlled trials   
De Waard 
1993 
(32)  
The 
Netherlands & 
Poland 
 
Risk of bias: 
3/10 (high) 
 
102 post-menopausal women 
Stage NR (no signs of distant 
metastases) 
Mean time post-diagnosis NR 
(recruited soon after recovery 
from surgery/radiotherapy) 
Mean BMI NR (eligibility: BMI 
≥27kg/m2) 
Mean age NR (eligibility: 50-
69yrs) 
Ethnicity NR 
 
Recruited through hospitals   
a)  Initial individual, face-to-face dietitian-delivered 
counselling with variable follow-up for 1 or 3yrs; aim 
of 10kg weight loss; balanced diet of 1500kcal/d; 
(1000kcal/d if insufficient weight loss was noted) 
b) Control (no details reported) 
 
Intervention duration/follow-up: 1-3yrs 
 
a) approx. -6kg.  
b) NR 
 
 
Retention: 73.5% 
 
Missing data: completers 
analysis 
 
 
Djuric 2002 
(33) 
USA 
 
Risk of bias: 
3/10 (high) 
 
48 pre & post-menopausal 
women  
Stage I or II breast cancer 
Mean 4yrs post-diagnosis (free of 
recurrence) 
Mean BMI 35.5kg/m² (eligibility: 
30-44kg/m²) 
Mean age 52yrs (eligibility: 18-
70yrs) 
73.0% Caucasian; 25% African 
American  
 
a)  Weight Watchers: weekly group meetings for 1yr 
(coupons provided free of charge) 
b)  Individualized: telephone dietitian-delivered contact  
weekly (months 1-3), biweekly (months 4-6), and 
monthly (months 7-12). Monthly group, face-to-face 
meetings were encouraged, not required. Written 
materials/brochures provided monthly. Specified 
energy intake (calculated from current body weight 
and deficit of 500-1000kcal/d); 20-25% energy from 
fat; 20% protein; 5 servings/d of fruit & vegetables; 
30-45min/d moderate physical activity most days of 
week; pedometers provided for self-monitoring and 
goal-setting  
c) Comprehensive: both a) and b) for 1yr 
Change from baseline to 12-
months: 
a) -2.7 ± 2.1 kg 
b) -8.0 ± 1.9 kg†  
c) -9.5 ± 2.7 kg† 
d) +1.1 ± 1.7 kg  
b vs. d‡; c vs. d‡ 
 
%BFc a vs. c‡, b vs. d‡ and c 
vs. d‡ 
 
 
Retention: 81.3% 
 
Missing data: unclear  
14 
 
Recruited through direct mail; 
press releases; brochures at breast 
clinics 
d) Control: National Cancer Institute’s ‘healthy eating’ 
pamphlets  
 
Intervention duration: 12mo 
Post-intervention follow-up: no 
Mefferd 2007 
(34) 
USA 
 
Risk of bias: 
2/10 (high) 
 
85§ pre & post-menopausal 
women 
Stage I-IIIa breast cancer 
Mean 3.5yrs post-diagnosis 
(diagnosed within  14yrs)  
Mean BMI 31.0kg/m² (eligibility: 
≥25kg/m2) 
Mean age 56yrs (eligibility: 
≥18yrs) 
93% Caucasian  
 
Recruited through cancer 
registry, clinician referral, 
community advertising (local 
newspaper, community events) 
a) Group, face-to-face weekly sessions for 16wks and bi-
weekly telephone counselling for weeks 1-2 then 
weekly. Goal of 500-1000kcal/d energy deficit by 
reducing energy density; high-fibre vegetables, whole 
grains and fruit encouraged; goal of 60min/d of  
moderate to vigorous physical activity; strength 
exercise 2-3 times/wk; increased lifestyle activity 
(pedometer provided); cognitive behavioral therapy, 
goal setting, self-monitoring and cognitive 
restructuring; facilitator unclear  
b) Wait-list control: usual care 
 
Intervention duration/follow-up: 16wksǁ 
Post-intervention follow-up: no 
Change from baseline to 16 
weeks: 
a) -5.7 ± 3.5 kg†  
b) -0.2 ± 4.1 kg  
a vs. b‡ 
 
WCa‡; HCa‡; WHR; total 
BF (DXA) ‡; trunk FM‡; leg 
FM‡; LBM 
 
Retention: 89.4% 
 
Missing data: completers 
analysis 
Shaw 2007 
(35)  
UK 
 
Risk of bias: 
3/10 (high) 
 
24§ women with documented 
lymphedema secondary to 
breast cancer (menopausal 
status NR)  
No stage restrictions 
Mean time post-diagnosis NR 
(remission from cancer and no 
chemotherapy/radiotherapy in 
the previous 12mo) 
Mean BMI 32.0kg/m² (eligibility: 
≥25kg/m2) 
a)   Weight-reduction: individualized, dietitian-delivered 
dietary advice (frequency of contact unclear); energy 
deficit of 1000kcal/d; specific reduction of fat and 
refined carbohydrates;  
b)  Control: healthy eating booklet 
 
Intervention duration/follow-up: 12wks 
Post-intervention follow-up: no 
 
Change from baseline to 12 
weeks: 
a) -3.3 ± 2.6 kg† 
b) 0.0 ± 3.0 kg 
a vs. b‡  
 
Skinfold thickness 
 
 
Retention: 87.5% 
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Mean age 60yrs (eligibility: NR) 
Ethnicity NR 
 
Recruited from a lymphedema 
Clinic and the Lymphedema 
Support Network 
Missing data: completers 
analysis 
 
Shaw 2007 
(40) 
UK 
 
Risk of bias: 
4/10 
(moderate) 
 
64§ women with documented 
lymphedema secondary to 
breast cancer (menopausal 
status NR) 
No stage restrictions 
Mean time post-diagnosis NR 
(remission from cancer and no 
chemotherapy/radiotherapy in 
the previous 12mo) 
Mean BMI 27.2kg/m² (eligibility: 
NR) 
Mean age 65yrs (eligibility: NR) 
Ethnicity NR 
 
Recruited through a lymphedema 
clinic 
a)  Weight-reduction: individualized, dietitian-delivered 
advice (frequency of contact unclear); reduced-energy 
intake of 1000-1200kcal/d; specific reduction of high 
fat and refined carbohydrate foods;  
b)  Low-fat diet: individualized, dietitian delivered advice 
(frequency of contact unclear); 20% energy from fat; 
recommended increased carbohydrate intake to 
maintain energy intake;  
c) Control: continue with habitual diet 
 
Intervention duration: 6mo 
Post-intervention follow-up: no 
 
Change from baseline to 6 
months: 
a) -4.0 ± 2.7 kg† 
b) -2.6  ± 3.0 kg† 
c) -0.6 ± 3.0 kg 
a vs. c‡; b vs. c‡  
 
Skinfold thickness (sum of 
4 sites) ‡, %BF‡ 
 
 
Retention: 79.7%  
 
Missing data: completers 
analysis 
 
Djuric 2009 
(37) 
USA 
 
Risk of bias: 
4/10 
(moderate) 
24 pre & post-menopausal 
women 
Stage I-IIIa breast cancer 
Mean 5.6yrs post-diagnosis 
(diagnosed within 10yrs; no 
recurrence/second primary 
tumour) 
Mean BMI 36.6kg/m² (eligibility: 
30-45kg/m2) 
All participants (initial 6-months): one face-to-face 
dietitian-delivered counselling session, then telephone 
sessions – weekly (months 1-3) then biweekly (months 4-
6). Weight watchers coupons provided for weekly 
attendance and a monthly newsletter. Aim for 10% body 
weight loss; energy deficit of 500-1000kcal/d; 20-25% 
energy from fat; 20% protein; 6-8 serves/d of fruit and 
vegetables; 30min of exercise on at least 5 days. 
Change from baseline to 18 
months: 
a) -1.9% (sd NR) 
b) -1.5% (sd NR) 
a vs. b (ns) 
 
 
Retention: 71.0% 
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Mean age 55yrs (eligibility:18-
70yrs) 
100% African American 
 
Recruited through clinics; 
presentations; mailing to breast 
cancer support group; newspaper 
adverts 
a) Dietitian counselling only: continued intervention with 
monthly telephone calls for 12 months 
b) Spiritually-tailored dietitian counselling: in addition, 
telephone-delivered spiritual counselling – weekly 
(months 1-3), biweekly (months 4-6) then monthly 
(months 7-12)  
 
Intervention duration/follow-up: 18mo 
Post-intervention follow-up: no 
Missing data: completers 
analysis 
 
Thomson 
2010 (36) 
USA 
 
Risk of bias: 
3/10 (high) 
40 post-menopausal women 
Stage I or II ER+ breast cancer 
Mean 3.7yrs post-diagnosis 
(treatment completed within 
previous 4yrs) 
Mean BMI 31.8kg/m² (eligibility: 
25.0-34.9kg/m²) 
Mean age 56yrs (eligibility: 50-
60yrs) 
82% Caucasian 
 
Recruited through a cancer center 
a)   Low fat/High carbohydrate diet: individualized, face-
to-face, dietitian-delivered counselling; weekly for 6 
weeks followed by the 6 month intervention. 
Individualized energy intake (deficit of 500kcal/d); 55-
60% energy from carbohydrates; 25% fat; 15-20% 
protein  
b) Reduced carbohydrate diet: individualized, face-to-
face, dietitian-delivered counselling; weekly for the 
first 6 weeks of the 6 month intervention.  
Individualized energy intake (deficit of 500kcal/d); 
35% energy from carbohydrates; 25-30% protein; 35-
40% fat; instructed to reduce carbohydrates to <30g/d 
in first 2wks to induce ketosis 
 
Intervention duration/follow-up: 6mo 
Post-intervention follow-up: no 
Change from baseline to 6 
months:  
a) -6.3 ± 5.6 kg† 
b) -5.9 ± 4.1 kg† 
a vs. b (ns) 
 
WCa,b, WHR, %BF 
(DXA)a,b, appendicular 
LBM (DXA)a,b 
  
 
Retention: 80.0% 
 
Missing data: baseline 
observation carried forward  
Greenlee 2012 
(38)  
USA 
 
Risk of bias: 
5/10 
(moderate) 
42 pre & post-menopausal 
women  
Stage 0-IIIa breast cancer 
Mean 4.1 years post-diagnosis 
(treatment completed at least 
6mo prior; no 
recurrence/metastasis) 
a)  Curves weight management program- (commercial 
gym/weight loss program); free gym membership; 3 
face-to-face exercise training sessions with a Curves 
trainer and : 6 x 1hr weekly, group sessions with 
Curves instructor for nutrition course (commenced 
about 1 month after exercise program); target goal of 
3-5 days/wk exercise session at gym; 1200kcal/d for 1-
Change from baseline to 6 
months:  
a) -2.9 ± 3.2 kg† 
b) -1.4 ± 2.5 kg† 
a vs b‡ 
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mean BMI 33.2kg/m² 
(eligibility: >25 kg/m²) 
Mean age 51yrs (eligibility: 21-
70yrs) 
79% Hispanic; 21% African 
American 
 
Recruited through a breast 
oncology clinic 
2 wks then 1600kcal/d; 45% energy from protein; 30% 
carbohydrates; 25% fat; weekly motivational telephone 
calls from instructor during 6 week nutrition course.  
b)  Wait-list control arm 
 
 
Intervention duration/follow-up: 6mo 
Post-intervention follow-up: yes – 6mo (immediate 
intervention arm only) 
WCa, HC, % BF (DXA) a, 
FM kg (DXA) a, LBM kg 
(DXA) 
 
  
Retention: 90.5% 
 
Missing data: completers 
analysis  
 
 
Harris 2012  
(39) 
USA 
 
Risk of bias: 
4/10 
(moderate) 
52§ pre & post-menopausal 
women 
Stage I-IIIa breast cancer 
Mean time post-diagnosis NR 
(treatment completed within 
previous 2-36mo)   
Mean BMI 31.9kg/m² (eligibility: 
25-45kg/m²) 
Mean age 53yrs (eligibility: 30-
75yrs) 
80% Caucasian 
 
Recruited through 
advertisements; physician 
referrals; breast cancer survivor 
groups 
a) ¥Group-based: 16 x 60-90min, group, face-to-face 
sessions over 6-months; facilitated by a trained 
interventionist; goal of 150 min/wk moderate physical 
activity; dietary goals to achieve 0.5-1kg weight 
loss/wk (following Diabetes Prevention Program 
guidelines). Months 7-12 – monthly, individual 
telephone contacts with interventionist.   
b)  ¥Telephone-based: individual, 15-60min, weekly 
telephone contacts for 6-months; delivered by 
commercial behavior change company personnel; 
physical activity and dietary goals same as group (a). 
Months 7-12 – monthly telephone  
 
Intervention duration/follow-up: 12mo 
Post-intervention follow-up: no 
 
Change from baseline to 12 
months: 
a) -2.0 (sd NR) kg  
b) -5.0 (sd NR) kg†  
a vs. b (NR) 
 
WC (NR)  
 
 
Retention: 78.8% 
 
Missing data: completers 
analysis 
 
 
Scott 2013 
(41)  
UK 
 
90 pre & post-menopausal women 
Stage I-III breast cancer 
Mean time post-diagnosis NR 
(treatment completes within 
previous 3-18mo) 
a) 24 weeks, 3 x weekly supervised exercise sessions (30 
mins aerobic + 10-15 mins resistance exercise); one-
to-one individualized dietary advice session + written 
information; + weekly, small group, nutrition 
education sessions; goal of 0.5kg weight loss/wk; 
Change from baseline to 24 
weeks (median [IQR]) 
a) -1.1 [-2.9, -0.2] kg†  
b) -0.4 [-1.8, 0.7] kg  
a vs. b (ns) 
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Risk of bias: 
8/10 (low) 
Mean BMI 30.3kg/m2 (eligibility: 
>25kg/m2)  
Mean age 56yrs (eligibility NR) 
98% Caucasian  
 
Recruited through hospital 
clinical trials center, local cancer 
support services, media or word 
of mouth 
energy intake (deficit of 600kcal/d); 25% energy from 
fat; at least 5 serves/d of fruit and vegetables. 
b) Control: general healthy eating booklet  
 
Intervention duration/follow-up: 24wks 
Post-intervention follow-up: no 
 
WCa, WHRa, %BF (BIA) 
 
 
Retention: 87.8%   
 
Missing data: multiple 
imputation  
Single-arm trials   
McTiernan 
1998  
(42)  
USA 
 
Risk of bias: 
2/6 (high) 
10 pre & post-menopausal women 
Stage I-II breast cancer 
Mean time post-diagnosis NR 
(range 1-5yrs post-diagnosis; 
treatment completed within 
previous 4mo) 
Mean BMI NR (eligibility: >25 
kg/m²) 
Mean age NR  (range: 40-74yrs;  
eligibility: 25-75yrs) 
90% Caucasian 
 
Recruited through oncology 
practices    
3 x weekly, individual or group, face-to-face supervised 
exercise sessions for 8wks delivered by an exercise 
physiologist; individually prescribed exercise program; 
between wks 4-8 patients exercise at home on non-
monitored days; gradual increase to 30-45 mins/d 
moderate-intensity aerobic activity/ day, 6 days/wk.  
1 x individual or group, face-to-face counselling session 
delivered by nutritionist; low-fat diet (20% energy from 
fat); high fruit and vegetable intake (8+/day) 
1 x telephone call in week 3 delivered by a nutritionist to 
assess adherence and provide additional counselling 
 
Intervention duration: 8 weeks 
Post-intervention follow-up: no 
Weight: -1.2 ± 1.4 kg† 
 
WC†; HC†; %BF (BIA)†; % 
LBM (BIA)†;  
 
Retention rate= 90% 
 
Missing data: completers 
analysis 
Stolley 2009  
(45)  
USA 
 
Risk of bias: 
4/6 (moderate) 
23 pre & post-menopausal women 
Stage I-III breast cancer 
Mean time post-diagnosis NR 
(treatment completed at least 6 
months prior) 
Mean BMI 34.1kg/m² (eligibility: 
≥25kg/m²) 
2 x weekly, group, face-to-face classes for 6 months; 1 x 
2hr class (address knowledge, attitudes, barriers, 
facilitators etc; + 60min exercise class) and 1 x 1hr 
exercise class delivered by local instructor 
 
Intervention duration: 6mo 
Post-intervention follow-up: no 
Weight: -2.5 (-3.9, -1.1) kg† 
 
Retention rate= 87.0% 
 
Missing data: completers 
analysis 
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Mean age 51yrs (eligibility: 
≥18yrs) 
100% African American  
 
Recruited through local chapters 
of national breast cancer support 
organisations 
 
 
Befort 2012 
(43)  
USA 
 
Risk of bias: 
4/6 (moderate) 
 
34 rural, post-menopausal women 
Stage I-IIIc breast cancer 
Mean time post-diagnosis NR 
(Mean 3.1yrs since treatment 
completion; treatment 
completed within previous 
10yrs) 
Mean BMI 33.7kg/m² (eligibility: 
27-45kg/m²) 
Mean age 59yrs (eligibility: 
<75yrs) 
97% Caucasian  
 
Recruited through rural cancer 
centers  
24 x 1hr weekly, group, telephone contacts using 
conference call, delivered by dietitian or clinical 
psychologist. Goal of 10% weight loss; 1000kcal 
reduction/d; ≥5 serves fruit & vegetables/d, approved pre-
packaged frozen dinners (2/d) or equivalent (soup, 
portion-control meal), shakes (2/d, provided); gradual 
increase to 225min moderate physical activity/wk 
 
Intervention duration: 24wks 
Post-intervention follow-up: no 
Weight: -11.6 ± 6.5 kg† 
 
WC† 
 
Retention rate= 91% 
 
Missing data: completers 
analysis and baseline 
observation carried forward  
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Campbell 
2012 
(44)  
Canada 
 
Risk of bias: 
4/6 (moderate) 
 
14 pre & postmenopausal women 
Stage I-IIIa breast cancer 
Mean time post-diagnosis NR 
(Mean 2.1yrs since treatment 
completion; diagnosed within 
5yrs; treatment completed 
within previous 3mo) 
Mean BMI 30.1kg/m² (eligibility: 
25-35kg/m²) 
Mean age 55yrs (eligibility: 
>18yrs) 
 
Recruited through referral from 
their oncologist; word of 
mouth; poster advertising 
16 x 2hr group, face-to-face, dietitian-delivered sessions; 
weekly (weeks 1-8) and bi-weekly (weeks 9-24); 
individual energy strategies provided based on weight 
loss goal of 7% baseline weight (specific amounts of 
energy were not prescribed); 20% energy from fat; 
gradual increase to 150min/wk of moderate to intense 
physical activity including 2 x 45min sessions/wk of 
supervised exercise  
 
Intervention duration: 24wks 
Post-intervention follow-up: yes (12 weeks) 
Weight: -3.8 ± 5.0 kg† 
 
WC†; HC†; total FM 
(DXA)†; %BF (DXA)†; 
LBM (DXA)†   
 
Retention rate= 100% 
 
Missing data: completers 
analysis for some outcomes 
with missing data (n=10-13) 
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C-Reactive Protein (CRP) was measured in four trials (36; 38; 41; 44), with none reporting 
significant within- or between-group differences. Only one trial measured other inflammatory 
markers (TNF, IL-6, IL-8, VEGF) and observed no between-group differences, despite 
significant between-group differences in weight loss (47). Two trials (41; 42) measured 
several sex hormones and observed no significant within- or between-group changes, though 
weight loss was minimal. 
 
Psychosocial outcomes and treatment-related side-effects 
Psychosocial indices and treatment-related side-effects are shown in Table 3. QOL was 
assessed in two of the RCTs (41; 49) and two single-arm trials (44; 45), with mixed effects. 
Two studies reported significant intervention effects on QOL (41; 44) (despite one trial 
observing minimal weight loss), one reported significant associations with weight loss (49), 
and one reported no significant change in QOL (45). Depression was measured in one RCT, 
with no significant difference in change in depression scores between the intervention groups 
(37); and in one single-arm trial which observed a significant improvement (43).   
 
Three RCTs (35; 40; 49) and one single arm trial (43) assessed treatment-related side-effects. 
Excess arm volume as a measure of lymphedema was measured in two studies (35; 40), with 
one  observing a significant reduction in the intervention group compared to control (35), 
whereas the other observed similar reductions across both intervention groups and the control 
group (40); baseline levels of excess arm volume were considerably higher in the latter study. 
In both trials, weight loss was significantly correlated with changes in excess arm volume 
(35; 40). Darga et al. (49) reported a significant association between weight change and 
fatigue at 12-months, but did not report between-group differences. Befort et al. (43) 
observed no significant change in fatigue or cognitive function, but observed statistically 
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significant improvements in body image and joint pain, and a trend toward reduced hot 
flashes, in their single-arm trial. 
 
Dietary intake and physical activity 
Seven RCTs reported changes in dietary intake (33; 35-38; 40; 41) and four reported changes 
in PA or fitness levels (34; 37; 38; 41). Two RCTs reported measuring PA, but did not report 
results (33; 36). Two did not report on either behavior (32; 39). All single-arm trials reported 
on changes in dietary intake and physical activity. Significant between- and within-group 
changes in these outcomes are shown in Table 3. In the studies which reported changes in 
dietary intake and/or PA, weight loss was generally supported by reductions in total energy 
intake and fat intake, and increases in PA.   
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Table 2. Changes in cancer-related biomarkers in randomized clinical trials and single-arm studies of weight loss interventions in women with 
breast cancer  
 
Biomarker Study/Author Study group N % body 
weight 
loss 
% change in biomarker Sample & assay details 
Insulin / Insulin 
resistance 
Djuric 2002 & 
Jen 2004  
(33,46) 
a) Weight-watchers arm 
b) Individualized arm 
 
c) Comprehensive arm 
 
d) Control   
8 
 
9 
 
10 
 
12 
a) -2.8% 
 
b) -8.8% 
 
c) -9.5% 
 
d) +1.2% 
Insulin: 13.2% 
HOMA-IR: 5.0%   
Insulin: 23.2% 
HOMA-IR: 30.0%  
Insulin: 26.1%  
HOMA-IR: 17.6%  
Insulin: 17.7% 
HOMA-IR: 17.1% 
Fasting blood sample 
Batch assay NR 
Insulin: Not clear  
Glucose: Not clear 
 Thomson 2010 
(36) 
a) Low-fat diet 
 
 
b) Reduced-
carbohydrate diet 
21 
 
 
19 
a) -7.6%  
 
 
b) -6.9% 
Insulin: 28.3%  
HOMA-IR: 30.0% † 
HbA1c: 3.3%  
Insulin: 15.5% † 
HOMA-IR: 16.7% † 
HbA1c: 1.7% † 
Fasting blood sample 
Batch assay  NR 
Assay NR 
 Greenlee 2010 
(38) 
a) Curves program 
 
b) Wait-list control 
20 
 
17 
a) -3.3% 
 
b) -1.8% 
Insulin: 4.5% 
HOMA-IR: 5.0%  
Insulin: 5.6%  
HOMA-IR: 4.9%  
Fasting blood sample 
Batch assays conducted 
Insulin: RIA 
Glucose: automated 
chemistry analyzer 
 Scott 2013 
(41)  
 
a) Weight loss 
intervention 
b) Control  
43 
 
40 
a) -1.3% 
 
b) -0.5% 
HOMA-IR: 5.3% 
 
HOMA-IR: 13.1%  
Fasting blood sample 
Batch assays conducted 
Insulin: ELISA 
 Befort 2012 
(43)  
 
Weight loss 
intervention 
31 -13.9% Insulin: 42.9% † Fasting blood sample 
Batch assays conducted 
ELISA 
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 Campbell 2012 
(44) 
Weight loss 
intervention 
13 -4.9% Insulin: 28.3%  
HOMA-IR: 30.3%  
Fasting blood sample 
Batch assays conducted 
Assay NR 
IGF & IGFBP Greenlee 2010 
(38) 
a) Curves program 
 
 
b) Wait-list control 
17 
 
 
21 
a) -3.3% 
 
 
b) -1.8% 
IGF-I: 15.1% 
IGFBP-1: 24.5% 
IGFBP-3: 13.3%  
IGF-I: 11.4%  
IGFBP-1: 19.5% 
IGFBP-3: 2.4% 
Fasting blood sample 
Batch assays conducted 
ELISA 
 Scott 2013 
(41)  
 
a) Weight loss 
intervention 
 
b) Control  
43 
 
 
40 
a) -1.3% 
 
 
b) -0.5% 
IGF-I: 2.8%  
IGFBP-1: 11.8% 
IGFBP-3: 6.8%  
IGF-I: 2.0%  
IGFBP-1: 5.2%  
IGFBP-3: 2.7%  
Fasting blood sample 
Batch assays conducted 
ELISA 
Leptin Djuric 2002 & 
Jen 2004  
(33,46) 
a) Weight-watchers arm 
b) Individualized arm 
c) Comprehensive arm 
d) Control   
8 
9 
10 
12 
a) -2.8% 
b) -8.8% 
c) -9.5% 
d) +1.2% 
3.0%   
30.4%  
41.6% † 
14.3%  
 
Fasting blood sample 
Batch assay NR 
Assay not clear  
 Scott 2013 
(41)  
 
a) Weight loss 
intervention 
b) Control  
43 
 
40 
a) -1.3% 
 
b) -0.5% 
11.9% *  
 
16.7% 
Fasting blood sample 
Batch assays conducted 
ELISA 
 Befort 2012 
(43)  
 
Weight loss 
intervention 
31 -13.9% 42.5% †  Fasting blood sample 
Batch assays conducted 
ELISA 
Adiponectin (total) Greenlee 2010 
(38) 
a) Curves program 
b) Wait-list control 
22 
20 
a) -3.3% 
b) -1.8% 
18.2% 
31.9% 
Fasting blood sample 
Batch assays conducted 
RIA 
 Befort 2012 
(43)  
Weight loss 
intervention 
31 -13.9% 2.1% Fasting blood sample 
Batch assays conducted 
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 ELISA 
CRP Greenlee 2010 
(38) 
a) Curves program 
b) Wait-list control 
22 
20 
a) -3.3% 
b) -1.8% 
41.6%  
2.6% 
Fasting blood sample 
Batch assays conducted 
High sensitivity CRP – 
automated chemistry 
analyzer 
 Thomson 2010 
(36) 
a) Low-fat diet 
b) Reduced-
carbohydrate diet 
21 
19 
a) -7.6% 
b) -6.9% 
9.1%  
6.8%  
Fasting blood sample 
Batch assay NR 
High sensitivity CRP  - 
automated turbidimetry 
analyzer 
 Scott 2013 
(41)  
 
a) Weight loss 
intervention 
b) Control  
43 
 
40 
a) -1.3% 
 
b) -0.5% 
7.3%   
 
1.4%  
Fasting blood sample 
Batch assays conducted 
Assay NR 
 Campbell 2012 
(44) 
Weight loss 
intervention  
13 -4.9% 44.4%  Fasting blood sample 
Batch assays conducted 
Assay NR 
Other inflammatory 
markers 
 
Mefferd 2007  
& Pakiz 2011 
(34,47)  
a) Weight loss 
intervention 
 
 
b) Wait-list control  
44 
 
 
 
24 
a) -6.8% 
 
 
 
b) 0.2% 
TNF-α: 8.5% † 
IL-6: 17.6%  
IL-8: 6.3%  
VEGF: 14.3% 
TNF-α: 14.8% * 
IL-6: 17.6%  
IL-8: 2.2%  
VEGF: 10.3% 
Fasting NR 
Batch assays conducted 
ELISA 
Sex Hormones Scott 2013 
(41)  
 
a) Weight loss 
intervention 
 
 
b) Control 
43 
 
 
 
40 
a) -1.3% 
 
 
 
b) -0.5% 
Estradiol: 7.5% 
Estrone: 5.5% 
Testosterone: 0% 
SHBG: 5.0% 
Estradiol: 20.0% 
Estrone: 0.9% 
Fasting blood sample 
Batch assays conducted 
Estradiol & estrone by 
ELISA 
Testosterone & SHBG NR 
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Testosterone: 6.2% 
SHBG: 1.2% 
 McTiernan 
1998 
(42)  
Intervention 8 -1.5% Total estradiol: 12.5% 
Free estradiol: 5.4% 
Total estrone: 7.1% 
Estrone sulphate: 18.8% 
Total testosterone: 4.1% 
Free testosterone: 7.7% 
Androstenedione: 7.1% 
SHBG: 8.3% 
DHEA: 7.1% 
DHEA-Sulphate: 10.7% 
Fasting blood sample 
Batch assays conducted 
Estradiol, estrone, 
testosterone & 
androstenedione by RIA 
SHBG & DHEA not clear 
 
 
Table 3. Changes in psychosocial indices, treatment-related side-effects, dietary intake and physical activity reported in randomized clinical 
trials and single-arm trials of weight loss interventions in women with breast cancer 
 
Study Psychosocial indices & treatment 
related side-effects 
Dietary intake Physical Activity 
Randomized Controlled trials 
de Waard 1993 
(32)  
 
 
- - - 
Djuric 2002, Jen 
2004 & Darga 
2007  
(33,46,49) 
 
Quality of Life (FACT-Anemia): 
NR 
 
Fatigue (FACIT-Fatigue): 
NR 
3 day food records:  
Energy intake abc  
Total fat (%E) ab  
 
Physical activity logs: 
NR 
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Mefferd 2007 & 
Pakiz 2011  
(34,47) 
 
- - 7-day physical activity recall 
Moderate-vigorous PA* 
Shaw 2007 
(35)  
 
Lymphoedema (arm circumference 
measurements): 
Excess arm volume (%)* 
7-day diary: 
Energy intake* 
Total fat (g/d)* 
Protein (g/d) 
Carbohydrates (g/d)*  
 
- 
Shaw 2007 
(40)  
 
 
 
Lymphoedema (arm circumference 
measurements or Perometer): 
Excess arm volume 
7-day diary: 
Energy intake* 
Total fat (g/d and %E)* 
Protein (g/d) * 
Carbohydrates (g/d)*  
- 
Djuric 2009 
(37) 
 
Depression (CES-D): 
Depression score 
Food frequency questionnaire 
(Block):  
Total fat (%E) ab 
Fruit (serves/1000kcal)* 
Vegetables (serves/1000kcal)b 
Healthy Eating Index a 
 
7-day physical activity recall: 
Physical activity 
 
Thomson 2010 
(36) 
 
- Food frequency questionnaire 
(Arizona):  
Energy intake ab 
Total fat (g)* 
Protein (g)* 
Carbohydrates (g)* 
 
Arizona Activity Frequency 
Questionnaire:   
NR 
 
Greenlee 2012 
(38)  
- Food frequency questionnaire 
(Block): 
Kaiser physical activity survey 
(adapted): 
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 Energy intake b
Total fat (%E) 
Protein (%E)* 
Fiber (grams) 
Fruits & vegetables (servings) 
Whole grains (servings) 
 
Household/caregiving index 
Active living index  
Sports/exercise index* 
 
Harris 2012 
(39) 
 
- - - 
Scott 2013 
(41) 
 
Quality of life (FACT-G and FACT-
B): 
FACT-G* 
Breast subscale* 
3-day diary: 
Energy intake 
Total fat (g)* 
Saturated fat (g)* 
Protein (g) 
Carbohydrates (g) 
Fitness (8-min walking test): 
Predicted VO2 max* 
Single-arm trials 
McTiernan 1998 
(42) 
 
- Food frequency questionnaire 
(Block): 
Total fat (g/d and %E)† 
Vegetables (serves/d) 
Fruit (serves/d)  
 
Physical activity logs: 
NR 
Stolley 2009 
(45) 
 
Quality of life (FACT-G, FACT-B 
and FACT-ES): 
FACT-G 
Breast subscale 
FACT-ES 
Food frequency questionnaire 
(Block): 
Energy intake 
Total fat (g/d† and %E) 
Fiber (g/d and g/1000kcal†) 
Vegetables (serves/d)† 
Fruit (serves/d) 
 
 IPAQ (Long form): 
Walking 
Moderate activity  
Vigorous activity†  
Total PA  
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Befort 2012 
(43) 
 
Quality of Life (Breast cancer 
prevention trial symptom checklist) 
Cognitive symptom subscale 
Musculoskeletal subscale† 
Vasomotor subscale 
 
Fatigue (Brief fatigue inventory) 
 
Depression (Patient health 
questionnaire [PHQ-9]) 
Depression score† 
 
Body image (Body Image and 
Relationship Scale) 
Strength and health† 
Social barriers† 
Appearance and sexuality† 
  
24-hour dietary recall: 
Energy intake† 
Fruit and vegetables (serves/d)† 
Total fat (%E)† 
Minnesota Physical Activity 
Questionnaire:     
kcal/wk† 
min/wk† 
Campbell 2012 
(44) 
 
Quality of life (FACT-B) † 3 day food records:  
Energy intake  
Total fat (g/d and %E)   
 
Fitness (maximal graded treadmill 
test): 
VO2 max† 
Metabolic equivalent (hrs/wk)† 
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Adverse events 
Only three-of-ten RCTs (38; 39; 41) and one-of-four single-arm trials (44) reported on 
adverse events, with none reporting any serious adverse events. Only one study reported an 
adverse event directly related to the intervention (upper arm fracture) (44).   
 
Ongoing Trials 
Five ongoing trials are shown in Table 4. Two of these (SUCCESS-C and DIANA-5) are 
fully-powered trials evaluating the impact of a lifestyle-based, weight loss intervention on 
disease-free survival and breast cancer recurrence (50; 51). The LISA trial was originally 
designed to evaluate the effect of a lifestyle-based weight loss intervention on disease-free 
survival in post-menopausal women (52); however, following loss of funding, the trial 
recruited only 338 of the planned 2,150 participants (53). The trial will follow these 
participants to evaluate longer-term effects and secondary outcomes. The ENERGY trial was 
designed as a vanguard trial to first establish efficacy for achieving and maintaining weight 
loss and improvements in QOL among 693 breast cancer survivors (54). Pending successful 
outcomes, funding will be sought to expand to a fully-powered trial to evaluate breast cancer 
recurrence and disease-free survival. The CHOICE study is a non-randomized trial, 
evaluating the effect of two weight loss interventions (with differing macronutrient 
compositions) versus control group on changes in various metabolic and hormonal 
biomarkers (55).  The SUCCESS-C, LISA and ENERGY trials are also evaluating the effect 
of the interventions on incidence of co-morbidities and related outcomes.  
 
DISCUSSION  
This review summarizes the intervention trial evidence on the benefits of weight loss in 
women with breast cancer. There is a small but growing body of evidence to suggest that 
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weight loss is feasible and safe in women following treatment for breast cancer. Studies have 
generally focused on weight loss as the primary outcome, with over half also reporting on 
changes in central obesity (waist circumference). However, very few studies have reported on 
psychosocial and treatment-related outcomes, and with the exception of fasting lipids, 
glucose and insulin, few have measured other cancer- and chronic disease-related biomarkers.  
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Table 4. Ongoing trials of weight loss interventions in women with breast cancer 
Study Sample Characteristics Study groups Outcomes to be assessed 
SUCCESS C 
(50; 96-99) 
Germany 
 
3642 pre & post-menopausal women 
Her2/neu-negative and axillary lymph 
node metastasis or high-risk node-
negative (defined as pT ≥2, 
histopathological grade 3, age 
≤35yrs or negative hormone 
receptor) early stage breast cancer; 
no distant disease 
Surgery not more than 6wks prior 
BMI eligibility: 24-40kg/m² for second 
randomization 
Age eligibility: ≥18yrs 
 
Recruitment via multiple cancer 
centers (no further details 
specified).  
 
Recruitment finished in 2011. 
 
2x2 factorial design 
First randomization:  
a) 3 cycles of FEC (epirubicin, 
fluorouracil, cyclophosphamide) 
chemotherapy, followed by 3 cycles 
of docetaxel or 
b) 6 cycles of docetaxel-
cyclophosphamide 
Second randomization (n=2292 based 
on BMI eligibility):  
a) Lifestyle intervention – 
Individualized, telephone, lifestyle 
coach-delivered intervention over 
2yrs (team of nurses, dietitians, 
physicians, psychologists; 20 phone 
calls); weight loss aim of 5-10% in 
first 6mo followed by weight 
maintenance; specified energy 
intake (deficit of 500-1000kcal/d); 
20-25% energy from fat; 150-
200min/wk moderate, progressive 
physical activity; pedometers 
supplied; individual behavioral and 
motivational lessons; workbook 
provided; regularly mailed 
newsletters  
b) Control – mailed information on 
general health after randomization/ 
chemotherapy and at 1 year 
  
Primary outcome: 
Disease-free survival 
 
Secondary outcomes: 
Obesity-related biomarkers (e.g. 
insulin, adiponectin, other 
adipokines) 
Genetic markers (e.g. genetic 
variations in germline DNA and 
tumor DNA) 
Circulating tumor cells (CTCs) 
Incidence of type 2 diabetes, 
hypertension and coronary heart 
disease 
 
Estimated completion: late 2016 
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Follow-up planned for 5yrs 
LISA Trial 
(52; 53) 
North America 
 
338 postmenopausal women*  
Stage I-IIIa breast cancer (hormone 
receptor positive), no recurrent or 
metastatic disease 
On adjuvant hormonal therapy with 
Letrozole at time of recruitment 
Definitive surgery within previous 3yrs 
BMI eligibility: 24-40kg/m² 
Age eligibility: not specified 
Exclusions include:  insulin-requiring 
diabetes, history of other 
malignancies (excluding non-
melanoma skin cancers) 
 
Recruited through 20 cancer centers in 
Canada and USA  
 
*Terminated recruitment after 338 of a 
planned 2150 due to loss of funding 
a) Intervention – Individualized, 
telephone-delivered intervention 
over 2yrs (19 calls in total) plus 
manual and mailings. Weight loss 
aim of 10%; energy reduction 
(deficit of 500-1000kcal/d); 20% 
energy from fat; 150-200min/wk of 
moderate physical activity. 
b) Control – Mail based education 
only; 2yr subscription to health 
magazine  
 
Primary outcome: 
Disease-free survival 
 
Secondary outcomes: 
Overall survival 
Distant disease-free survival 
Non-cancer medical events (e.g. 
diabetes, cardiovascular disease, 
arthritis) 
Health-related quality of life (SF-36) 
Biomarkers (e.g. insulin)  
 
Estimated completion: mid 2018 
DIANA-5 
(51; 100) 
Italy 
1417 pre & post-menopausal women 
Invasive breast cancer, no distant 
metastasis, local recurrence or 
second primary breast cancer 
Diagnosed within previous 5 years 
(chemotherapy treatment 
completed) 
High risk of recurrence defined as: ER- 
tumor, or high serum testosterone or 
insulin level, or metabolic 
syndrome 
BMI eligibility: not specified 
a) Intervention (Mediterranean-
macrobiotic lifestyle) – Group, face-
to-face sessions; 4 cooking classes 
and 10 meetings in first year, 
meetings every 2 months in year 2, 
every 3 months in year 3 and every 
4 months in years 4-5; monthly 
physical activity classes in year 1. 
Intervention messages consistent 
with WCRF/AICR 
recommendations. 210 min/wk 
moderate physical activity over at 
Primary outcomes: 
Breast Cancer recurrence (new 
primary, locoregional or distant 
recurrence) 
 
Secondary outcomes: 
Hormonal and metabolic biomarkers 
such as blood lipids, glucose, 
insulin, HOMA, testosterone, 
SHBG 
Biomarkers of food intake such as 
carotenoids, polyphenols 
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Age eligibility: 35-70yrs 
Exclusions include: other cancer 
diagnoses in previous 10yrs 
(excluding non-melanoma skin 
cancer) 
 
Recruited clinics site; tumor registries; 
hospitals; screening units; support 
groups; media 
 
Recruitment completed 
 
least 3 days; decrease sedentary 
behavior by 30min/d on at least 5 
days; moderate calorie restriction  
(relative to expenditure); reduce 
energy density and glycemic index 
of foods; reduce animal protein 
(except fish). Print materials 
provided; monthly magazine   
b) Comparison – Leaflet with 
WCRF/AICR recommendations; 2-
3 meetings annually 
Anthropometric measures  
 
Estimated completion: not reported 
CHOICE 
(55; 101; 102) 
USA  
259 post-menopausal women 
No evidence of metastatic disease 
At least 4 months post-treatment 
BMI eligibility: 25-34.9kg/m² 
Exclusions include: diabetes, hepatitis 
B, C or HIV, cigarette smokers, weight 
loss ≥ 2kg in previous month  
 
Recruited through single cancer clinic 
 
Non-randomized trial: participants 
allowed to choose 1 of 3 arms;   
 
a) Low carbohydrate-high fat diet – 
macronutrient composition 32% 
carb, 48% Fat, 20% Protein; deficit 
500 kcal/d (in combination with 
physical activity and caloric intake 
restriction); provided with six-
weeks of meal plans for specified 
calorie level and other supporting 
materials; attend up to 10 one-on-
one clinic visits and 5 group visits; 
physical activity 10000 steps/d 
recommendation (provided with 
pedometer)   
b) Low fat-high carbohydrate diet – as 
for (a) but macronutrient 
composition 64% carb, 16% Fat, 
20% Protein  
Primary outcome: 
High sensitivity CRP 
 
Secondary outcomes: 
Other inflammatory markers (IL-6, 
TNF-a) 
Glucose homeostasis (glucose, insulin, 
HOMA, IGF-1, IGFBP-3, IGF-
1:IGFBP-3) 
Cellular oxidation (8-hydroxy-deoxy-
guanosine, 8-isoprostane-F2-alpha) 
Hormone metabolism (estradiol 
estrone progesterone, SHBG) 
Adipokines (leptin, adiponectin, 
ghrelin)   
Body composition (via BOD POD) 
 
Estimated completion: June 2012 
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c) Control – general information for 
breast cancer patients on weight 
management 
ENERGY Trial 
(54; 103) 
USA 
 
693 pre & post-menopausal women 
Stage I-III breast cancer diagnosed 
within previous 5yrs; completion of 
initial therapies 
BMI eligibility: 25-45 kg/m2 
Age eligibility: ≥21yrs 
 
 
Exclusions include: history of other 
malignancies (excluding non-
melanoma skin cancer), insulin 
requiring diabetes 
 
Recruited through cancer registries, 
clinics, media and community support 
groups and events. 
 
Recruitment completed May 2012. 
 
 
 
a) Intervention – Group-based, 
cognitive-behavioral weight loss 
program; weekly one-hour group 
sessions for 4 months, followed by 
fortnightly sessions for 2 months, 
then monthly sessions for 6 
months. In addition, individual 
telephone and/or email contacts 
(10-15 mins), aiming for 14-16 
contacts in year 1 and total of 24-
38 calls/emails over 2yrs. 
Individually tailored newsletters 
provided quarterly from 6-24 
months. Aim for 7% weight loss at 
2 years; reduction in energy intake 
(500-1000 kcal/d deficit) via 
decreasing energy density; goal of 
at least 60min/d moderate-intensity 
planned exercise; strength training 
2-3 times/wk; increasing lifestyle 
activity (10000 steps/d; pedometers 
provided). Provided with 
workbook, food and exercise 
journals, calories counter, digital 
scale 
b) Control (less intensive) – provided 
with general weight management 
resources and materials; individual 
counselling session at baseline and 
Primary outcome: 
Weight change 
 
Secondary outcomes: 
Quality of life (SF-36) 
Assessment of co-morbidities 
Blood biomarkers and genetic markers 
(individual markers not specified) 
 
*This trial is designed as a vanguard 
trial. Results of this trial will inform 
recruitment of a larger cohort to 
conduct a fully powered trial to 
evaluated disease-free survival 
 
Estimated completion: mid 2014 
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6-months (calorie level prescribed 
[1200-2000kcal/d]; at least 
30mins/d physical activity 
recommended); monthly telephone 
call from study coordinator 
(standardized script to stay in touch 
and update details); invited to 
attend information sessions on 
healthy living every two months in 
year 1 
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Weight loss interventions that addressed a combination of diet, PA and behavior modification 
(considered best practice for management of overweight and obesity (56; 57)) generally 
achieved mean within-group weight losses ≥5% initial body weight (33; 34; 39; 43; 44), 
however some did not (37; 39; 45). Interventions where the PA and dietary components were 
more segregated (e.g., supervised exercise sessions) and with less focus on behavior 
modification tended to achieve less weight loss (38; 41; 42).  Consistent with what has been 
observed in other studies (58), there is some evidence to suggest that longer interventions 
(>6-months) achieved greater weight loss.  Similar to weight loss interventions conducted in 
non-cancer survivor ethnic groups (59), the three studies that targeted ethnic breast cancer 
survivors (37; 38; 45) achieved small mean weight losses (between 1.5-3.3% initial body 
weight), suggesting that more research is needed in developing interventions that are 
effective among minorities (59). Despite the importance of long-term weight loss 
maintenance (defined as maintaining weight loss for at least 12-months (60)), only two of the 
14 randomized and single-arm trials assessed whether weight losses (and changes in other 
outcomes) were maintained after the intervention ceased, and follow-up for both were 6-
months or less (38; 44).  
 
Obesity has been postulated to influence breast cancer progression via a number of biological 
pathways which center on insulin, and other adipokine, inflammatory and hormonal 
mechanisms with significant cross-talk amongst them (48; 51; 61; 62). Recent reviews 
suggest that modest intentional weight loss (i.e., 5-10% body weight) can improve hormonal 
(e.g., estradiol) and inflammatory (e.g., CRP, TNF-a and IL-6) biomarkers (63), insulin 
resistance and plasma leptin concentrations (64), although these findings are based on studies 
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in non-cancer survivors. Effects of modest intentional weight loss on IGFs appear to be 
smaller and inconsistent (63) and insufficient to induce changes in total adiponectin 
concentrations (64; 65). Reviews on the effects of exercise-only interventions on biomarkers 
in a small number of trials in breast cancer survivors have shown minimal or inconsistent 
effects on insulin, IGFs and inflammatory markers (66-68).  
 
The current review identified that in women following treatment for breast cancer, intentional 
weight loss of ≥5% was associated with reductions in insulin and leptin of 30-40%. 
Reductions in CRP were less consistent and changes in other inflammatory markers and 
adiponectin appeared unrelated to weight loss. This evidence however, is based on a small 
number of generally underpowered studies. A recent study by Rock et al. (69) indicated that 
in women diagnosed with early stage breast cancer in the previous 10 years, those who lost 
≥5% of body weight, had significantly greater reductions in insulin (22%) and leptin 
(44%) and increases in sex hormone binding globulin (SHBG; 22%) than women who lost 
<5% of body weight over  6-months. After 18-months, the improvement in leptin 
concentrations was maintained, although the effect on insulin and SHBG had diminished 
(69). Further controlled trials in larger samples are needed to understand the influence of 
intentional weight loss on cancer-related biomarkers in breast cancer survivors. This research 
should be conducted alongside the advances in identification of biomarkers most salient to 
breast cancer. Also of particular relevance for breast cancer survivors, is assessment of 
comorbidity-related outcomes. In older breast cancer survivors, cardiovascular disease 
accounts for more deaths than breast cancer (70). Weight loss and lifestyle changes 
(increased physical activity and healthy diet) are important for reducing risk and improving 
management of chronic diseases such as cardiovascular disease and type 2 diabetes (22). 
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The negative impact of breast cancer and its treatment on psychosocial outcomes and QOL is 
well documented (71).  Although most women return to pre-morbid functioning around 12-
months post-diagnosis (72), a sizeable percentage (over 60%) experience multiple treatment-
related side-effects which are reported many years after diagnosis (73). These downstream 
effects may be exacerbated by obesity and weight gain post-diagnosis (74; 75). Evidence 
from weight loss interventions in non-breast cancer survivors suggests that weight loss can 
improve QOL (76) and hot flashes (77). Furthermore, PA has been shown to improve many 
of these outcomes in breast cancer survivors (25). Weight loss may therefore be beneficial for 
improving psychosocial and treatment-related outcomes in breast cancer survivors, however 
only a small number of the studies included in this review assessed such outcomes. These 
studies suggest that a weight loss intervention may be beneficial for improving QOL, 
lymphedema, fatigue, depression, body image, joint pain and hot flashes (35; 40; 43; 44; 49). 
Future trials of weight loss interventions in breast cancer survivors should include a more 
comprehensive assessment of patient-reported outcomes. Inclusion of a control group, or 
more specifically an attention-control group, in future trials is important to further inform the 
extent to which beneficial effects on such outcomes can be attributed to weight loss versus 
more generic support/attention (78; 79).  
 
No serious adverse events were reported in any of the trials included in this review. 
Reductions in LBM are common with weight loss (80; 81), with significant loss of LBM 
increasing the risk of sarcopenia and functional impairment (80; 82). Two studies (36; 44) 
included in this review reported significant within-group reductions in LBM after the six-
month interventions. These trials evaluated diet-only interventions, with no emphasis on PA 
(36) or promoted aerobic exercise only (44). Resistance exercise is important for preserving 
LBM during weight loss (80; 82; 83) while weight bearing exercises are important for 
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preserving bone mineral density (BMD) (84). Obesity, in particular abdominal and visceral 
adiposity, are associated adversely with bone health, including lower BMD, likely as a result 
of the metabolic complications associated with obesity (85). Furthermore, breast cancer 
treatments (chemotherapy and some hormonal therapies) may induce bone loss and increase 
risk of osteoporosis and fractures (86). Therefore, preserving BMD during intentional weight 
loss is important to minimize further bone loss. No trials in this review examined changes in 
BMD during intervention. The evidence from this review supports the safety of weight loss in 
women following breast cancer treatment, but suggests that resistance and weight bearing 
exercise is likely to be important to prevent loss of LBM and BMD.  
 
There are a number of limitations with the studies in this review. Many were considered to 
have high risk of bias. None assessed whether changes in outcomes were maintained long-
term and none assessed cost-effectiveness. This evidence is important for informing decisions 
about resource allocation relevant to the translation and uptake of such interventions into 
practice (87). Furthermore, most studies recruited women a considerable time post diagnosis. 
There is no clear evidence on the best time to intervene regarding weight loss following a 
breast cancer diagnosis. Intervening early is likely to have the greatest impact on reducing 
morbidity and mortality from chronic diseases, such as cardiovascular disease and diabetes 
(88; 89), and presumably also improving breast cancer outcomes. Addressing weight loss in 
women closer to diagnosis and end of treatment may capitalize on the ‘teachable moment’ of 
the breast cancer diagnosis (90) for some women, whereas for others, this time is associated 
with high levels of distress (91). Very few studies assessed and reported on changes in diet 
and PA, which underpinned the weight loss interventions. Measuring changes in PA, 
including objective measurement via accelerometers, can be useful to determine the extent to 
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which improvements in outcomes, such as psychosocial indices, are due to weight loss 
overall, or to increases in PA independent of weight loss. 
 
Results from the ongoing trials will provide important evidence as to the effect of weight loss 
on breast cancer endpoints such as disease-free survival, QOL and possible mechanisms by 
which weight loss improves breast cancer prognosis. A number of these studies are 
evaluating ‘scalable’ interventions that may have the potential to be translated into practice 
(with two evaluating interventions delivered solely via telephone). Development of 
interventions designed to be implemented within the context of usual care and thus mindful 
of resource requirements will be an increasingly important consideration for future studies. 
Evidence on the effectiveness of ‘scalable’ interventions for achieving weight loss in non-
cancer survivor groups has shown: promising results for telephone delivery (92); small, 
inconsistent effects of web-based interventions delivered via computer (93; 94); and limited 
evidence to date for mobile phone SMS-based interventions (95).  Testing of such 
interventions among cancer survivors will be an increasingly important consideration for 
future studies. 
 
Table 5. Recommendations for future weight loss intervention trials in women with breast 
cancer 
 
Study methodology 
 Aim to recruit women closer to treatment completion and  report on mean time post-
diagnosis as part of baseline characteristics 
 Inclusion of control group; consideration of an attention control group 
 Improve reporting of trial outcomes in accordance with CONSORT guidelines 
 Power on outcomes other than anthropometric outcomes 
 Assess maintenance of outcomes at least 6-months after intervention completion 
 Assess impact of interventions on specific subgroups of breast cancer patients, e.g., 
those with luminal A, luminal B, and triple negative disease 
42 
 
Intervention 
 Assess the impact of multiple component interventions that include dietary energy 
restriction, physical activity and behavior change strategies 
 Interventions should include resistance and weight-bearing exercises to preserve lean 
body and bone mass 
 Further develop culturally-appropriate, ethnic-specific interventions 
 ‘Scalable’ interventions that have the potential to be translated into practice should be 
evaluated  
Outcomes Assessed 
 Assess and report on patient-reported outcomes (such as quality of life, fatigue, hot 
flashes, lymphedema etc.) and chronic disease- and cancer-related biomarkers 
 Assess changes in dietary intake and physical activity (including objectively measured 
physical activity) 
 Assess changes in waist circumference and body composition (including regional 
adiposity) to understand changes in body weight. 
 Assess changes in lean body mass and bone mineral density to ensure no negative 
effects of the intervention on these outcomes 
 Conduct cost-effectiveness analyses  
 
 
The evidence to date on weight loss interventions in breast cancer survivors suggests that 
weight loss is feasible, effective (particularly multi-component interventions) and safe. 
Recommendations for future weight loss trials in patients following treatment for breast 
cancer are shown in Table 5. Ongoing trials, such as SUCCESS C, DIANA-5, ENERGY, and 
LISA, will provide future evidence on the benefits of purposeful weight loss on disease-free 
survival and QOL. Even so, continued research will be necessary to fine-tune the supportive 
strategies that are most effective in this patient population (and important sub-groups such as 
underserved minorities), and that can be implemented broadly in the context of usual care. 
Further trials will also help to build the evidence on the potential benefits for patients and 
health care costs, to assist in advocating for the provision of such programs so that they are 
routinely offered to overweight and obese breast cancer patients as part of their routine 
follow-up care.    
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Table 1: 
* Weight loss served as primary outcome 
¦ Bias score based on a 10-item checklist (refer to Tables S1 and S2) 
† p<0.05 for within group change for weight and other outcomes as reported by authors 
(italicized indicates that this has been calculated from mean and standard deviation reported) 
‡ p<0.05 for between group difference for weight and other outcomes  
Different superscripts indicate p<0.05 within group differences for other outcomes  
§ Baseline data for mean age and mean BMI is based on completers, not total randomized 
sample 
ǁ Manuscript describes a 12-month intervention but only 16-week outcomes reported    
¥ Allocation to study groups not randomized 
Abbreviations: %BF, percent body fat; BF, body fat; BIA, bioelectrical impedance; BMI, 
body mass index; DXA, Dual-energy X-ray Absorptiometry; ER+, estrogen receptor positive; 
FM, fat mass; HC, hip circumference; IQR, interquartile range; LBM, lean body mass; NR, 
not reported; ns, not significant; WC, waist circumference; WHR, waist to hip ratio. 
 
 
Table 2: 
† p<0.05 for within group change if reported by authors (italicised indicates that this has been 
calculated from mean and standard deviation reported) 
* p<0.05 for between group difference as reported by authors 
Abbreviations: DHEA, dehydroepiandrosterone; ELISA, Enzyme-linked immunosorbent 
assay; HOMA-IR, homeostasis model assessment – insulin resistance; HbA1c, Glycated 
hemoglobin; IGF-I; Insulin-like growth factor 1; IGFBP-I; Insulin-like growth factor-binding 
protein 1; IGFBP-3; Insulin-like growth factor-binding protein 3; IL-6, interleukin-6; IL-8, 
interleukin-8; NR, not reported; RIA: radioimmunoassay; SHBG, sex hormone-binding 
globulin; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor  
 
Table 3: 
* p<0.05 for between group differences for outcomes in randomized controlled trials   
Different superscripts indicate p<0.05 for within group differences for outcomes for 
randomized controlled trials   
† p<0.05 for within group differences for outcomes in single-arm trials   
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Abbreviations: %E, percent of total daily energy intake; CES-D, Center for Epidemiological 
Studies Depression Scale; FACIT, Functional Assessment of Chronic Illness Therapy; 
FACT-B, Functional Assessment of Cancer Therapy – Breast Cancer Subscale; FACT-ES, 
Functional Assessment of Cancer Therapy – Endocrine Symptoms Subscale; FACT-G, 
Functional Assessment of Cancer Therapy – General;  IPAQ, International Physical Activity 
Questionnaire; NR, not reported; PA, physical activity 
 
Table 4: 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; DNA, deoxyribonucleic 
acid,  HOMA, homeostatic model assessment; IGF-I, insulin-like growth factor-I; IGFPB-3, 
insulin-like growth factor binding protein-3; IL-6, interleukin-6; NR, not reported; SHBG, 
sex hormone binding globulin; TNF-α, tumor necrosis factor alpha; WCRF/AICR, World 
Cancer Research Fund/ American Institute for Cancer Research 
 
 
Figure 1. PRISMA flow chart of studies through the review process 
 
